Eisele Jeffrey 4
4 · Apellis Pharmaceuticals, Inc. · Filed Dec 28, 2023
Insider Transaction Report
Form 4
Eisele Jeffrey
Chief Development Officer
Transactions
- Sale
Common Stock
2023-12-27$60.23/sh−235$14,154→ 53,580 total - Sale
Common Stock
2023-12-26$57.86/sh−68$3,935→ 53,815 total
Footnotes (2)
- [F1]This represents shares sold to cover tax withholding on a Restricted Stock Unit release.
- [F2]Sale originated from established 10b5-1 trading plan.